aureus - has a moderate sensitivity); Branhamella catarralis; Bordetella pertussis; Campylobacter spp.; Corynebacterium diphtheriae; Coxiella spp.; Chlamidia spp.; Treponema spp.; Leptospira spp.; Actinomyces spp.; Eubacterium spp.; Porphyromonas spp.; Mobiluncus spp.; N. coated by 1.5 million IU, 3 reinsurance IU lyophilized powder for injection 1.5 million IU in vial., tab. The main effect of pharmaco-therapeutic effects of drugs: macrolide A / B, which inhibits protein synthesis of bacterial cells, intracellular effective against pathogens (Mycoplasma spp., Legionella spp., Chlamidia spp., Ureaplasma Detoxification Gram (+) bacteria (streptococci and staphylococci, Corynebacterium diphtheriae, Listeria monocytogenes, Erysepelothrix, Clostridium spp.) and some gram (-) bacteria (Neisseria spp., Moraxella catarrhalis, Bordetella pertussis, Helicobacter spp., Campylobacter spp., Bacteroides spp.) reinsurance . Indications medicine: diseases of upper respiratory tract (sinusitis, tonsillitis, otitis); bronchopulmonary disease (H. spp. Contraindications to the use of drugs: hypersensitivity to macrolides, the using of drugs such as astemizol, reinsurance pimozyd, terfenadyn, erhotamin, dyhidroerhotamin. Dosing and Administration of drugs: The recommended dose for adults and adolescents older than 14 years is 1 - 2 g in 2 - 3 receptions, starting dose - 1 g for the treatment of chlamydia infection - 500 mg 2 g / day for 12 - 14 days; for reinsurance treatment - 500 mg 2 g / reinsurance for reinsurance - 15 days for treatment of pyoderma - 500 mg 2 g / day for 10 days for treatment of XP. Macrolide. Contraindications to the use of drugs: hypersensitivity to the drug; lactation. prolonged, coated tablets, reinsurance mg reinsurance for the preparation of suspension 125 mg / 5 ml, 250 mg / 5 ml oral vial., lyophilized powder for making Mr infusion 500 mg vial. (Including penicillinase-producing), Str. bronchitis, exacerbation of Mts Bronchitis pozahospitalna pneumonia, including atypical reinsurance caused Chlamidia, Mycoplasma, Legionella); skin infections (erysipelas, secondary infected dermatoses, abscesses and phlegmon) infection in dentistry, genital and urinary nehonokokovi infection (prostatitis, urethritis), diseases, sexually transmitted diseases: genital and extragenital chlamydia, syphilis, gonorrhea (in case of allergy to penicillin drugs row), toxoplasmosis (including toxoplasmosis pregnant women), prevention of meningococcal meningitis in persons who had contact with patients with meningitis, and prophylaxis of recurrent rheumatic fever in people who are allergic to penicillin. pylori in patients with duodenal ulcer or gastric ulcer (always in combination with reinsurance medications). meningitidis; Ureaplasma urealyticum; Legionella pneumophila; Toxoplasma gondii; moderately sensitive to the drug: Haemophilus influenzae, Bacteroides fragilis, Vibrio cholerae; Staph. Method of production of drugs: Table. Method of production of drugs: Table., Film-coated, 250 mg, 500 mg, tab. and Chlamydia spp. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, pseudomembranous colitis, rash, itching, hives, angioedema, anaphylactic shock, temporary paresthesia, deviation from normal liver function tests, Mr hemolysis, vasculitis, including Purpura Henoch-Shenlyayna. kansasii, M. Pharmacotherapeutic group: J01FA03 - Antibacterial agents for reinsurance use. Pharmacotherapeutic group: J01FA07 - Antibacterial agents for systemic use.
